IMC-2017 is under clinical development by ImmuneCyte and currently in Phase I for Spinal Cord Disorders. According to GlobalData, Phase I drugs for Spinal Cord Disorders have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IMC-2017’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMC-2017 overview
IMC-2017 is under development for the treatment of spinal fusion. It comprises of autologous stem cells. It is being developed based on AutoSTEM platform.
ImmuneCyte overview
ImmuneCyte, a subsidiary of HealthBanks Biotech (USA) Inc, is a biopharmaceutical company that includes research and development of cell and gene therapies for cancer, vascular, orthopedic and aging-related diseases. It is investigating drugs against critical limb ischemia (CLI) and diabetic foot ulcer (DFU); orthopedic diseases including osteoarthritis, non-union fracture, avascular necrosis and spinal fusion. The company is also evaluating programs for the treatment of premature aging, premature ovarian failure, non-Hodgkin lymphoma, multiple myeloma, melanoma, metastasized breast cancer, renal cell carcinoma and other immune-oncology and hematology indications. ImmuneCyte utilizes its proprietary CARTXpress manufacturing platform to develop cell-based immunotherapies. It operates with an additional office in Tianjin, China. ImmuneCyte is headquarter in Irvine, California, the US.
For a complete picture of IMC-2017’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.